Sterling Capital Management
RNA icon

Sterling Capital Management’s Atrium Therapeutics RNA Stock Holding History

Sterling Capital Management’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.44K Buy
415
+290
+232% +$3.42K ﹤0.01% 3012
2026
Q2 		$1.68K Buy
125
+25
+25% +$327 ﹤0.01% 3034
2026
Q1 		$1.34K Buy
+100
New +$1.4K ﹤0.01% 3052

Other funds holding RNA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Trium Capital
Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
AlphaCentric Advisors
AlphaCentric Advisors San Juan, Puerto Rico $113M AUM 27.37% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Kestra Private Wealth Services
Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Sterling Capital Management's RNA Position: Q3 2026 in Review

Sterling Capital Management increased its Atrium Therapeutics (RNA) stake by 232% in Q3 2026, buying an estimated $3.42K and bringing the position to 415 shares worth $3.44K. The position accounts for ﹤0.01% of the portfolio, ranked #3012.

Sterling Capital Management first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. 38 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Sterling Capital Management held 415 shares of Atrium Therapeutics worth $3.44K as of Q3 2026.
  • Sterling Capital Management bought 290 Atrium Therapeutics shares in Q3 2026, an estimated $3.42K.
  • Atrium Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #3012 holding.
  • Sterling Capital Management first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 38 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.